This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

MiRNAs Evaluate the Prognosis of Sepsis by Dynamic Study (METPSDS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2011 by Chinese PLA General Hospital.
Recruitment status was:  Recruiting
Information provided by:
Chinese PLA General Hospital Identifier:
First received: October 24, 2011
Last updated: October 25, 2011
Last verified: August 2011
Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to observe the selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis in order to be a new target for the treatment of sepsis.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: MiRNAhs in the Evaluation of the Value of Sepsis Prognosis Dynamics Observational Research

Resource links provided by NLM:

Further study details as provided by Chinese PLA General Hospital:

Primary Outcome Measures:
  • all cause mortality [ Time Frame: 28days after admited in ICU ]

Biospecimen Retention:   Samples Without DNA
human serum

Estimated Enrollment: 70
Study Start Date: August 2011
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Survival Group
Death Group

Detailed Description:
The study is a non-intervention observational study. Purpose of this study is to observe some selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis . The investigators will collect serum samples from patients with sepsis in SICU, RICU and EICU on the 1st、3rd、5th、7th、10th、14th day of 301 Hospital since November 2011 , and then use mirVana PARIS kit extract total RNA and use qRT-PCR detect miRNAS expression in serum which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
within 24 hours after admited in ICU

Inclusion Criteria:

  • Clinical diagnosis of sepsis
  • Patients who agree with the study

Exclusion Criteria:

  • Aged <18 years;
  • Into the group who died within 24 hours;
  • Agranulocytosis (<0.5 × 109 / L);
  • Combined HIV infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01459822

Contact: Jie Deng, master +86 18610095120

China, Haidian
Chinese PLA General Hospital Recruiting
Beijing, Haidian, China, 100853
Contact: China         
Sponsors and Collaborators
Chinese PLA General Hospital
Study Director: LiXin Xie, doctor Pneumology Department of chinese PLA General Hospital
  More Information Identifier: NCT01459822     History of Changes
Other Study ID Numbers: 301PLAGH-20110824005
Study First Received: October 24, 2011
Last Updated: October 25, 2011

Keywords provided by Chinese PLA General Hospital:

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes processed this record on August 17, 2017